Luye Pharma Group Ltd (LUP) - Total Liabilities

Latest as of June 2025: €15.49 Billion EUR ≈ $18.11 Billion USD

Based on the latest financial reports, Luye Pharma Group Ltd (LUP) has total liabilities worth €15.49 Billion EUR (≈ $18.11 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Luye Pharma Group Ltd cash conversion from operations to assess how effectively this company generates cash.

Luye Pharma Group Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how Luye Pharma Group Ltd's total liabilities have evolved over time, based on quarterly financial data. Check LUP financial resilience to evaluate the company's liquid asset resilience ratio.

Luye Pharma Group Ltd Competitors by Total Liabilities

The table below lists competitors of Luye Pharma Group Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Bumi Resources Minerals Tbk JK:BRMS	Indonesia	Rp185.57 Million
KEDE Numerical Control Co Ltd SHG:688305	China	CN¥392.19 Million
Yangtze Optical Electronic Co. Ltd. A SHG:688143	China	CN¥378.17 Million
Shenzhen Edadoc Technology Co. Ltd. A SHE:301366	China	CN¥621.62 Million
Winall Hi tech Seed SHE:300087	China	CN¥4.22 Billion
RITES Limited NSE:RITES	India	Rs33.18 Billion
Ramsay Generale De Sante PA:GDS	France	€5.41 Billion
Fras-le S.A SA:FRAS3	Brazil	R$4.46 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Luye Pharma Group Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Luye Pharma Group Ltd market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.31	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.05	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.48	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Luye Pharma Group Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Luye Pharma Group Ltd (2016–2024)

The table below shows the annual total liabilities of Luye Pharma Group Ltd from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	€13.86 Billion ≈ $16.20 Billion	+15.85%
2023-12-31	€11.96 Billion ≈ $13.99 Billion	-9.43%
2022-12-31	€13.21 Billion ≈ $15.44 Billion	-1.93%
2021-12-31	€13.47 Billion ≈ $15.75 Billion	+7.47%
2020-12-31	€12.53 Billion ≈ $14.65 Billion	+26.05%
2019-12-31	€9.94 Billion ≈ $11.62 Billion	+3.51%
2018-12-31	€9.60 Billion ≈ $11.23 Billion	+148.54%
2017-12-31	€3.86 Billion ≈ $4.52 Billion	+46.17%
2016-12-31	€2.64 Billion ≈ $3.09 Billion	--

About Luye Pharma Group Ltd

F:LUP Germany Drug Manufacturers - Specialty & Generic

Market Cap

$1.26 Billion

€1.08 Billion EUR

Market Cap Rank

#8416 Global

#1090 in Germany

Share Price

€0.27

Change (1 day)

-1.46%

52-Week Range

€0.21 - €0.48

All Time High

€0.70